A House panel found pharmaceutical companies exponentially increased drug prices to boost profits; CDC data show an increase in alcohol-related deaths, especially among women; 4 million more Americans enroll in Medicaid.
The Democrat-led House Oversight and Reform Committee found major pharmaceutical companies increased drug prices exponentially to boost profits and executives’ bonuses, taking advantage of Medicare rules, Politico reports. The announcement comes after an 18-month investigation into the pricing practices of 12 drug companies, including Bristol Myers Squibb and Teva Pharmaceuticals. The report found Celgene, which was acquired by Bristol in 2019, raised the price of Revlimid, a cancer medication, 22 times since it launched in 2005. The raises ultimately tripled the drug’s price, while reports show in 2014, increases were ordered so the company could meet its quarterly revenue targets.
New CDC data show that alcohol-induced deaths among adults aged 25 and over increased 43% between 2006 and 2018, compared with stable rates seen from 2000 to 2006. Analyses found that between 2000 and 2018, alcohol-induced deaths increased at a greater rate for both males and females residing in rural areas of the country compared with urban areas. Deadly conditions cited by the CDC include those associated with muscle, liver, heart, or brain damage due to alcohol consumption. Since 2000, the number of women dying from these complications has grown by 76%. However, the data does not account for 2020 rates, and more recent analyses show alcohol consumption rose sharply during the pandemic.
Between February and June of 2020, 4 million more Americans enrolled in Medicaid, marking an increase of 5.7%, after a slow decline in enrollment began in mid-2017, CNN reports. The coronavirus disease 2019 (COVID-19) pandemic has caused millions of individuals to lose their jobs and in some cases, their health insurance. Federal data showed over 2.4 million adults enrolled in the program in the Spring of 2020, in addition to 1.4 million children who enrolled in either Medicaid of the Children’s Health Insurance Program. The data includes statistics from all states except Arizona and Washington DC.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
2 Commerce Drive
Cranbury, NJ 08512